Hong Kong-listed Sino Biopharm (SBP GROUP, 01177) reported a net reduction of 40.35 million ordinary shares during June 2026, driven entirely by on-market repurchases that were subsequently cancelled.

• Share capital: Authorised share capital remained unchanged at 30.00 billion ordinary shares with a par value of HKD 0.025, equivalent to HKD 750.00 million.

• Issued shares: Outstanding shares fell to 18.71 billion from 18.75 billion at end-May. No treasury shares were held.

• Repurchase activity: – 4 June 2026: 40.35 million shares repurchased and cancelled. – Two additional buybacks on 10 and 17 June totalled 22.07 million shares; these had been repurchased for cancellation but were still pending cancellation as at 30 June.

• Equity commitments: Under the January 2026 acquisition of 100% of Hangzhou Hygieia Biomedical, Sino Biopharm will issue 14.60 million new shares to Dracoo Investment Limited—5.84 million shares scheduled for April 2028 and 8.76 million for April 2029—subject to prior shareholder approval obtained on 10 June 2025. No share options, warrants or convertible securities were outstanding.

• Public float: The company confirmed compliance with the Main Board’s minimum 25% public-float requirement as of 30 June 2026.

The latest monthly return indicates a focused capital-management strategy through share repurchases alongside a limited, deferred equity issuance tied to recent M&A activity.